Cookies

Like most websites The Pathologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subscribe to Newsletter
Diagnostics Biochemistry and molecular biology, Precision medicine, Screening and monitoring, Technology and innovation

Blockade Biosensors

Immune checkpoint blockade inhibitors have transformed the standard of care for patients battling a wide range of cancers – but why do less than a quarter of patients respond to these drugs? Currently, there is no quick, effective method of finding out whether a patient is responding to treatment. Testing can be performed by either biopsy or CT scan – but both approaches have disadvantages. Biopsies can be painful, invasive, and slow to yield results; scans can be inaccurate because they examine apparent tumor size rather than directly measuring treatment response.

To address this problem, researchers have designed a synthetic biosensor that could enable doctors to quickly identify whether or not a therapy is working – all via noninvasive analysis of proteases in patients’ urine (1). “We reasoned that, if patients are responding to the drug, it means [the] T cells are making proteases, and if they’re not responding, these proteases are not present, so the T cells are not active,” said senior author Gabe Kwong (2).

The sensors attach to an immune checkpoint blockade inhibitor while it travels toward the tumor. When it arrives, proteases from T cells and tumor cells activate the sensors, releasing fluorescent reporters designed to concentrate in urine. “These signals would be diluted in blood and would be very hard to pick up, but everything from your blood gets filtered through the kidneys,” said Kwong (2). “So, when we look at the urine, we get very concentrated signals which increase or decrease corresponding to whether the patients are responding or not.”

Kwong and his colleagues are also investigating machine learning techniques that can distinguish between different types of intrinsic resistance driven by either B2M or JAK1 gene mutations. Ultimately, they hope to differentiate between types of acquired resistance as well, so that patients who begin to exhibit resistance can quickly be moved to a more effective treatment.

Receive content, products, events as well as relevant industry updates from The Pathologist and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. QD Mac et al., Nat Biomed Eng, 6, 310 (2022). PMID: 35241815.
  2. Jerry Grillo (2022). Available at: https://b.gatech.edu/3KdUNj3.
About the Author
Liv Gaskill

During my undergraduate degree in psychology and Master’s in neuroimaging for clinical and cognitive neuroscience, I realized the tasks my classmates found tedious – writing essays, editing, proofreading – were the ones that gave me the greatest satisfaction. I quickly gathered that rambling on about science in the bar wasn’t exactly riveting for my non-scientist friends, so my thoughts turned to a career in science writing. At Texere, I get to craft science into stories, interact with international experts, and engage with readers who love science just as much as I do.

Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine

Register